Although NTCP inhibition with BLV results in elevated serum total bile acids, in preclinical studies, BLV does not result in increased hepatic intracellular bile acid concentrations that are observed with cholestatic liver diseases [31, 32]. This evidence concerns the gene SLC10A1 and Cholestatic liver disease.